GNCA News and Press, Genocea Biosciences Inc. From 06/04/19

Investment thesis Genocea Biosciences ( GNCA ) is a clinical-stage biopharmaceutical initially focused on vaccine development for herpes simplex virus-2 (HSV2) and Streptococcus pneumoniae or pneumococcus, using antigen discovery platform ATLAS. Clinical studies for HSV2 demonstrated some ef...

Shares of Genocea Biosciences ( GNCA ) have gained around 40% since my May 2018 Reader Inquiry piece explored the company's pivot in focus from a late-stage immunotherapy candidate for the treatment of genital herpes to the lucrative yet crowded immuno-oncology arena. So far in 2019, share...

Gainers:  Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...

Genocea Biosciences (NASDAQ: GNCA ) +94%  on positive GEN-009 data in cancer patients. More news on: Genocea Biosciences, Inc., Cypress Semiconductor Corporation, Outlook Therapeutics, Inc., Stocks on the move, Read more ...

Genocea Biosciences (NASDAQ: GNCA ) reports clinical results from its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

    Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8 + T cell responses to 53% of vaccine neoantigens Conference call and webcast to discuss results TODAY at 8:30 am ET CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) --...

Gainers:  Stellar Biotechnologies (NASDAQ: SBOT ) +55% . Genocea Biosciences (NASDAQ: GNCA ) +52% . Mmtec (NASDAQ: MTC ) +27% . Capital Senior Living Corporation (NYSE: CSU ) +18% . Genesco (NYSE: GCO ) +13% . Williams-Sonoma (NYSE: WSM ) +13% . GTx (NASDAQ: GTXI ) +12% . Charl...

Thinly traded nano cap Genocea Biosciences (NASDAQ: GNCA ) is up  3%  premarket on increased volume (~30K shares) on the heels of its announcement that the Journal of Clinical Oncology has selected its presentation of Phase 1/2a results on investigational neoantigen vaccine GEN...

Poster presentation tomorrow, June 1 st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3 rd at 8:30 am ET CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company de...

CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess the potential of applying Genoce...